Fandom

VroniPlag Wiki

Ww/014

< Ww

31.268Seiten in
diesem Wiki
Seite hinzufügen
Diskussion0 Share

Störung durch Adblocker erkannt!


Wikia ist eine gebührenfreie Seite, die sich durch Werbung finanziert. Benutzer, die Adblocker einsetzen, haben eine modifizierte Ansicht der Seite.

Wikia ist nicht verfügbar, wenn du weitere Modifikationen in dem Adblocker-Programm gemacht hast. Wenn du sie entfernst, dann wird die Seite ohne Probleme geladen.

Validation of shRNA clones for gene silencing in 293FT cells

von Dr. Wen Wang

vorherige Seite | zur Übersichtsseite | folgende Seite
Statistik und Sichtungsnachweis dieser Seite findet sich am Artikelende
[1.] Ww/Fragment 014 01 - Diskussion
Zuletzt bearbeitet: 2014-10-28 02:53:55 Hindemith
Fragment, Gesichtet, KomplettPlagiat, Milhavet et al 2003, SMWFragment, Schutzlevel sysop, Ww

Typus
KomplettPlagiat
Bearbeiter
Graf Isolan
Gesichtet
Yes.png
Untersuchte Arbeit:
Seite: 14, Zeilen: 1-18
Quelle: Milhavet et al 2003
Seite(n): 643-644, Zeilen: 643:re.Sp. 51ff - 644:li.Sp. 1ff
The ability of RNAi to inhibit the replication or cellular uptake of viruses and other infectious agents has been clearly demonstrated in cell culture studies and, therefore, holds promise for the treatment of human patients. The ability of HIV-1 to infect cells and replicate can be severely compromised by targeting viral genes using siRNAs. Examples include the suppression of HIV-1 replication in human cells transfected with siRNA directed against the tat and the rev gene (Capodici et al, 2002; Jacque et al, 2002; Lee et al, 2002a; Novina et al, 2002). Transfection of human cells with siRNAs directed against different genes in the poliovirus genome resulted in resistance of the cells to infection with poliovirus (Gitlin et al., 2002). The ability of siRNAs targeting the gene encoding the death receptor Fas to protect mice from liver failure and fibrosis in two models of autoimmune hepatitis was tested by Song and colleagues (Song et al., 2003). Intravenous injection of Fas siRNA specifically reduced Fas protein levels in the livers of mice during a 10-day period. Fas siRNA treatment abrogated hepatocyte necrosis and inflammatory infiltration and markedly reduced serum concentrations of transaminases demonstrating a clear hepatoprotective effect of the siRNA therapy. [Seite 643]

The ability of RNAi to inhibit the replication or cellular uptake of viruses and other infectious agents has been clearly demonstrated in cell culture studies and, therefore, holds promise for the treatment of human patients. The ability of HIV-1 to infect cells and replicate can be severely compromised by targeting of

[Seite 644]

viral genes using siRNAs. Examples include the suppression of HIV-1 replication in human cells transfected with siRNA directed against tat and the rev gene (Capodici et al., 2002; Jacque et al., 2002; Lee et al., 2002a; Novina et al., 2002). Transfection of human cells with siRNAs directed against different genes in the poliovirus genome resulted in resistance of the cells to infection with poliovirus (Gitlin et al., 2002). The ability of siRNAs targeting the gene encoding the death receptor Fas to protect mice from liver failure and fibrosis in two models of autoimmune hepatitis was tested by Song and colleagues (Song et al., 2003). Intravenous injection of Fas siRNA specifically reduced Fas protein levels in the livers of mice during a 10-day period. Fas siRNA treatment abrogated hepatocyte necrosis and inflammatory infiltration and markedly reduced serum concentrations of transaminases demonstrating a clear hepatoprotective effect of the siRNA therapy.

Anmerkungen

Ohne Hinweis auf eine Übernahme.

Sichter
(Graf Isolan), Hindemith


vorherige Seite | zur Übersichtsseite | folgende Seite
Letzte Bearbeitung dieser Seite: durch Benutzer:Hindemith, Zeitstempel: 20141028025437

Auch bei Fandom

Zufälliges Wiki